Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity: 2020-2022

Historic Liabilities and Shareholders Equity for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2022 value amounting to $561.1 million.

  • Cullinan Therapeutics' Liabilities and Shareholders Equity fell 19.85% to $494.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.1 billion, marking a year-over-year decrease of 3.07%. This contributed to the annual value of $561.1 million for FY2022, which is 28.35% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Liabilities and Shareholders Equity of $561.1 million as of FY2022, which was up 28.35% from $437.2 million recorded in FY2021.
  • Over the past 5 years, Cullinan Therapeutics' Liabilities and Shareholders Equity peaked at $561.1 million during FY2022, and registered a low of $214.7 million during FY2020.
  • In the last 3 years, Cullinan Therapeutics' Liabilities and Shareholders Equity had a median value of $437.2 million in 2021 and averaged $404.3 million.
  • Data for Cullinan Therapeutics' Liabilities and Shareholders Equity shows a peak YoY spiked of 103.62% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows Cullinan Therapeutics' Liabilities and Shareholders Equity stood at $214.7 million in 2020, then soared by 103.62% to $437.2 million in 2021, then increased by 28.35% to $561.1 million in 2022.